Merck & Co., Inc. $MRK Stock Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 3.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 532,699 shares of the company’s stock after selling 19,456 shares during the quarter. Douglas Lane & Associates LLC’s holdings in Merck & Co., Inc. were worth $77,406,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Inspirion Wealth Advisors LLC bought a new stake in Merck & Co., Inc. in the third quarter valued at $240,000. Eclectic Associates Inc. ADV acquired a new position in Merck & Co., Inc. during the third quarter valued at approximately $301,000. LifeGoal Investments LLC bought a new stake in Merck & Co., Inc. in the 3rd quarter valued at $221,000. Market Street Wealth Management Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $200,000. Finally, Monument Capital Management raised its stake in shares of Merck & Co., Inc. by 0.7% in the third quarter. Monument Capital Management now owns 22,830 shares of the company’s stock valued at $3,317,000 after acquiring an additional 165 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock traded up $3.49 during mid-day trading on Friday, reaching $145.87. 3,216,070 shares of the company’s stock traded hands, compared to its average volume of 10,622,946. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The stock has a 50 day moving average of $143.59 and a two-hundred day moving average of $128.16. The company has a market cap of $359.89 billion, a price-to-earnings ratio of 116.63, a PEG ratio of 6.42 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the company earned $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.67 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Sanford C. Bernstein lifted their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday. UBS Group upped their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Finally, Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Seventeen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus price target of $151.32.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with PD-1/PD-L1 therapy. The decision expands Merck’s commercial oncology portfolio and could provide an additional growth opportunity alongside Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, adding a potentially valuable pipeline program. Merck Wins FDA Approval for WELIREG Plus LENVIMA
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while maintaining a neutral rating. The higher target reflects improved valuation support, although it implies limited upside at recent trading levels. Cantor Fitzgerald Raises Pharma Price Targets
• Neutral Sentiment: Analyst views remain divided: Morgan Stanley issued a buy rating in one report, while a separate report highlighted a pessimistic forecast. The conflicting outlooks suggest that Merck’s current valuation and future growth profile remain debated. Morgan Stanley Gives Merck a Buy Rating
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, but the relatively small holding is unlikely to materially affect the company’s fundamentals. Apella Capital Increases Merck Stake
• Negative Sentiment: A Dutch court blocked Merck’s subcutaneous Keytruda from being sold in eight European markets after Halozyme won an injunction in a patent dispute. The ruling could delay or restrict a potentially important, more convenient Keytruda formulation and increase litigation risk. Halozyme Wins Court Order Blocking Keytruda SC in Europe
• Negative Sentiment: Industry analysts identify Merck as one of the pharmaceutical companies most exposed to near-term generic competition as major patents expire. That patent-cliff risk could pressure revenue and earnings growth beyond the current period. Pharma Patent Cliff Risks

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.